# Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

> **NCT03532451** · PHASE1 · COMPLETED · sponsor: **PrECOG, LLC.** · enrollment: 43 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab/Lirilumab

## Key facts

- **NCT ID:** NCT03532451
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-22
- **Primary completion:** 2020-11-27
- **Final completion:** 2022-10-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532451, "Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03532451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*